NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

April 07, 2017

Finally, because of their innovative mechanisms of action, NK molecules and NK-102 constitute very promising neuroprotectants. They are capable of acting simultaneously on several cell types (neurons, glial cells...) through various pathways which confers them anti-apoptotic, anti-excitotoxic and anti-inflammatory properties.

The significant results obtained by NEUROKIN were published in August by the PLoS One Revue in an article entitled: ?« Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models ?»*.

J?©r??me BECQUART, CEO of NEUROKIN declared: ???This patent grant represents a keystone element of NEUROKIN??™s intellectual property and a recognition of the innovative nature of our approach already scientifically recognized with a publication in the PLoS One Revue. Our NK-102 candidate has great innovative potential in the treatment of the most serious central nervous system diseases and particularly stroke. In order to improve the preclinical regulatory and clinical development of its lead projects in stroke, epilepsy and TBI, Neurokin is currently seeking new investors???.

* PLoS ONE august 2010, volume 5, issue 8. B?©n?©dicte Menn (NEUROKIN), St?©phane Bach and Laurent Meijer (USR3151, CNRS) , Teri L. Blevins and Mark Campbell (MDS, Washington, USA), Serge Timsit (Department of Neurology, CHRU Brest, Facult?© de M?©decine et des Sciences de la Sant?© de Brest, Brest, France)